Across TCGA pan-cancer cohorts, MAP10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP10 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAP10 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, LIHC, and ACC are the cancer types where MAP10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.974	0.604	.001	34	view →
LIHC	OS	Median	All	0.031	0.775	<.001	9	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SCLC	OS	Median	All	1.000	0.241	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MAP10 tumor-vs-normal RNA expression · all MAP10 data types